Advancing the future of obesity
Vial is developing next-generation obesity therapeutics that precisely target fat loss while protecting lean muscle mass.
Vial's INHBE is developed as a combination therapy with GLP-1s and metabolic modulators.
- Increased fat loss while preserving lean mass
- Safety profile to support long-term treatment
- Normalize appetite signaling and glucose metabolism
Our Pipeline
Vial is developing INHBE, a small interfering RNA therapeutic, as a next-generation therapeutic for obesity and cardiometabolic indications.
Join the Future of Weight Management
We are currently enrolling participants in early-stage clinical studies. If you’re living with obesity or metabolic syndrome, you may qualify to participate in our groundbreaking research.
Contact
Get in touch!
Compose the future with us
"*" indicates required fields
